Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14678450 | 0.84 | BACE1 (0.46) | KMT2AEPHX2MDM4TP53 | |
| SCHEMBL29569298 | 0.84 | BACE1 (0.46) | KMT2AEPHX2MDM4TP53 | |
| SCHEMBL14677677 | 0.81 | KMT2A (0.53) | KMT2AEPHX2FABP5FABP7MDM4 | |
| SCHEMBL1721964 | 0.80 | KMT2A (0.43) | KMT2AEPHX2FABP5FABP7MDM4 | |
| SCHEMBL17438457 | 0.78 | ALDH1A1 (0.53) | — | |
| SCHEMBL17438458 | 0.78 | ALDH1A1 (0.53) | — | |
| SCHEMBL17438456 | 0.78 | ALDH1A1 (0.53) | — | |
| SCHEMBL1256624 | 0.77 | KMT2A (0.58) | KMT2AEPHX2FABP5FABP7MDM4 | |
| SCHEMBL4726879 | 0.77 | KMT2A (0.45) | KMT2AEPHX2FABP5FABP7MDM4 | |
| SCHEMBL3219970 | 0.76 | FABP5 (0.49) | KMT2AEPHX2FABP5FABP7OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056038-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2022-02-24 | — | — | US | disclosed |
| US-20200087313-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2020-03-19 | — | — | US | disclosed |
| EP-2736883-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | KARYOPHARM THERAPEUTICS INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9428490-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-08-30 | — | — | US | disclosed |
| EP-2736883-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013019561-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | XPO1, XPO5, XPOT | KMT2A 3078/4885EPHX2 4623/4885FABP5 2629/4885 |
| US-20200087313-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | KMT2A 3078/4885EPHX2 4623/4885FABP5 2629/4885 |
| US-20220056038-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | KMT2A 3078/4885EPHX2 4623/4885FABP5 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.